NGF-Driven Nociceptor Sensitization in Osteoarthritis
Osteoarthritic joints overproduce nerve growth factor, priming pain nerves.
- 595M: OA patients worldwide (adults affected globally)
- ~3×: NGF rise in OA joint (vs healthy synovium)
- 1956: NGF discovery (Nobel Prize awarded 1986)
- Hours: Sensitization onset (after local NGF rise)
Nerve growth factor floods the joint
Damaged cartilage and synovium ramp up NGF output.
Chondrocytes and synoviocytes both secrete NGF during flares.
Nociceptors become hyperexcitable
Elevated NGF primes sensory nerves to fire too easily.
A validated pain target
Blocking NGF interrupts pain before receptors ever engage.
NGF Binds TrkA Receptors on Sensory Nerve Endings
NGF locks onto TrkA receptors, igniting the pain pathway.
- ~pM: TrkA binding affinity (high-affinity NGF receptor)
- Trk: Receptor family (tropomyosin receptor kinases)
- MAPK/PI3K: Downstream cascade (sensitizing ion channels)
- p75NTR: Co-receptor (modulates TrkA affinity)
Lock-and-key receptor binding
NGF dimers dock precisely onto TrkA extracellular domains.
TrkA autophosphorylation fires within seconds of NGF binding.
Signal travels to the nerve terminal
Activated TrkA sensitizes ion channels like TRPV1 and Nav1.8.
A self-reinforcing pain loop
More NGF, more TrkA firing, more perceived joint pain.
Tanezumab Neutralizes Circulating and Local NGF
A humanized antibody scavenges NGF before it reaches receptors.
- IgG2: Antibody class (humanized monoclonal)
- NGF: Target (high specificity, high affinity)
- 8 wk: Dosing interval (typical subcutaneous schedule)
- Neutralizing: Mechanism (sequesters free NGF)
A Y-shaped molecular scavenger
Tanezumab's paratopes grip NGF, blocking its receptor face.
One antibody molecule can bind and disable one NGF dimer.
Dose-dependent neutralization
Higher antibody dose captures a larger share of free NGF.
Circulating and tissue NGF both fall
Antibody diffuses into synovium as well as bloodstream.
Antibody Prevents NGF From Ever Binding TrkA
Neutralized NGF can no longer trigger receptor activation.
- Up to 90%: TrkA activation drop (at high antibody dose)
- ~1 wk: Onset of relief (after subcutaneous dose)
- NGF-only: Selectivity (spares other neurotrophins)
- Upstream block: Mechanism type (acts before the receptor)
Upstream blockade beats downstream drugs
Removing the ligand stops signaling before it ever starts.
Unlike NSAIDs, tanezumab targets the pain driver directly.
Receptor occupancy collapses
With free NGF scarce, TrkA receptors sit unbound and quiet.
Downstream cascades go silent
MAPK and PI3K sensitization signals drop sharply.
Reduced Peripheral Sensitization Lowers Osteoarthritis Pain
Calmer nociceptors translate into measurable pain relief.
- ~45–62%: WOMAC pain reduction (in phase 3 OA trials)
- 8–16 wk: Response duration (per injection)
- RPOA: Joint safety watch (monitored rare risk)
- Regional: Approval status (varies by market)
Pain scores fall as sensitization eases
Patients report meaningfully lower joint pain on movement.
Effect wanes gradually as antibody clears over weeks.
Function often improves alongside pain
Reduced sensitization can restore daily mobility and activity.
Redosing sustains the effect
Repeat injections maintain NGF suppression over time.